the compounds of formula i are potent inhibitors of cox - 2 . cox - 2 activity was demonstrated by a cell - free assay in which human recombinant cox - 2 was incubated with test compound and [ 14 c ]- arachidonic acid . the resulting radiolabeled prostanoid compounds , i . e ., the products of cox - 2 reaction with arachidonic acid , were quantified . the compounds of the invention may be prepared via an intermediate of formula iv : the compounds of formula i are prepared by reacting the intermediate of formula iv with sulfamyl phenyl hydrazine hydrochloride . according to another embodiment of the invention a compound according to formula i may be further reacted with an anhydride of the formula wherein r 6 is c 1 - c 6 alkyl , to form the corresponding sulfonamide , that is , a compound according to formula v : and r 6 is defined as above . the corresponding alkali metal salt , that is , a compound where r 5 is and m is na , k or li , may be formed by reacting the above sulfonamide with an alkali hydroxide , selected from the group consisting of naoh , koh or lioh . the following are general procedures for preparation of the formula i compounds or intermediates thereof : to a solution of 10 % sodium hydroxide in ethanol ( 25 ml ), 1 , 1 , 1 - trifluoroacetone ( 10 mmol ) is added and stirred at 15 - 20 ° c . to this a solution of the appropriate araldehyde ( 10 mmol ) where z is defined as above , is added and stirred vigorously for 4 hrs . the temperature of the reaction is maintained at 15 - 20 ° c . throughout the reaction . the solution is then poured into ice water and acidified with concentrated hydrochloric acid . the resulting separated trans - 1 , 1 , 1 - trifluoro - 4 - aryl - 3 - buten - 2 - one of formula iv ( x = cf 3 ) is extracted with ether dried over anhydrous mgso 4 . evaporation of the dried ethereal layer yields the trans - 1 , 1 , 1 - trifluoro - 4 - aryl - 3 - buten - 2 - one which is purified by recrystallization . to a cooled solution of (− 70 ° c .) lithium diisopropylamide ( 10 mmol ), diethyl methylphosphonate ( 5 mmol ) is added . after the mixture is stirred for 30 minutes at − 70 ° c ., n - phenyltrifluoroacetimidoyl chloride ( 5 mmol ) is gradually added and stirring is continued at − 70 ° c . for 1 hour . the appropriate araldehyde ( 5 mmol ) where z is defined as above , is added dropwise for 10 minutes . the resulting mixture is warmed to room temperature over 2 hours and then stirred overnight . then 20 ml of dilute hydrochloric acid is added and stirred at room temperature for 4 hours . the solution is extracted thrice with diethyl ether ( 20 ml each time ) and washed successively with 5 % sodium bicarbonate and brine until the ph of the solution is 6 . the ethereal layer is separated , dried over anhydrous sodium sulfate and concentrated under reduced pressure to yield crude trans - 1 , 1 , 1 - trifluoromethyl - 4 - aryl - 3 - buten - 2 - one . the product is purified either by column chromatography or by recrystallization . the appropriate 1 , 1 , 1 - trihaloacetone can be substituted for 1 , 1 , 1 - trifluoroacetone in procedure 1 to provide other trans - 1 , 1 , 1 - trihalo - 4 - aryl - 3 - buten - 2 - one intermediate . similarly , other n - phenyltrihaloacetimidoyl chlorides can be substituted for n - phenyltrifluoroacetimidoyl chloride in procedure 1a to produce other trans - 1 , 1 , 1 - trihalo - 4 - aryl - 3 - buten - 2 - one intermediates . to a solution of 10 % sodium hydroxide in ethanol ( 25 ml ), a ketone of the formula wherein x is c 1 - c 6 alkyl ( 20 mmol ), or a radical of formula ii wherein r 3 and r 4 are defined as above ( 10 mmol ), is added and stirred at 15 - 20 ° c . to this a solution of the appropriate araldehyde ( 10 mmol ) where z is defined as above , is added and stirred vigorously for 4 hours . the temperature of the reaction is maintained at 15 - 20 ° c . throughout the reaction . the solution is then poured into ice water and acidified with concentrated hydrochloric acid . the resulting separated trans - 1 -( alkyl or optionally substituted aryl )- 3 - aryl - 2 - propen - 1 - one of formula iv ( x = c 1 - c 6 alkyl , or radical of formula ii ) is extracted with ether dried over anhydrous mgso 4 . evaporation of the dried ethereal layer yields the trans - 1 -( alkyl or optionally substituted aryl )- 3 - aryl - 2 - propen - 1 - one , which is purified by distillation or recrystallization . to a solution of a trans - 1 , 1 , 1 - trifluoro - 4 - aryl - 3 - butene - 2 - one ( 5 mmol ) of formula iv ( x = cf 3 ) in absolute methanol is added 4 - sulfamyl phenyl hydrazine hydrochloride ( 6 mmol ). the mixture is refluxed with stirring overnight on a hot plate with a stirrer . the solution is cooled and poured onto crushed ice and solid material is separated by filtration . recrystallization of the solid material with appropriate solvent yields the pure 1 -( 4 - sulfamylaryl )- 3 - trifluoromethyl - 5 - aryl - 2 - pyrazoline of formula ia : to a solution of a trans - 1 -( alkyl or optionally substituted aryl )- 3 - aryl - 2 - propen - 1 - one ( 5 mmol ) of formula iv in absolute methanol is added 4 - sulfamyl phenyl hydrazine hydrochloride ( 6 mmol ). the mixture is refluxed with stirring overnight on a hot plate with a stirrer . the solution is cooled and poured onto crushed ice and solid material is separated by filtration . recrystallization of the solid material with appropriate solvent yields the pure 1 -( 4 - sulfamylaryl )- 3 -( alkyl or optionally substituted aryl )- 5 - aryl - 2 - pyrazoline of formula i , wherein x is defined as in procedure 2 . to a solution of a 1 -( 4 - sulfamylphenyl )- 3 - trifluoromethyl - 5 - aryl - 2 - pyrazoline ( 10 mmol ) in tetrahydrofuran ( 40 ml ), acetic anhydride ( 20 mmol ), 4 - dimethylaminopyridine ( 10 mmol ) and triethylamine ( 11 mmol ) is added and stirred for 16 hours at room temperature . the reaction mixture is then poured into water ( 100 ml ) and extracted with ethyl acetate . the ethyl acetate layer is separated , washed successively with water , brine and then dried over anhydrous sodium sulfate . the dried organic layer is filtered and evaporated under reduced pressure to yield crude n -[ 4 -( 5 - aryl - 3 - trifluromethylpyrazolin - 1 - yl ) phenylsulfonyl ] acetamide . recrystallization from a mixed solvent yields a pure compound . other sulfonamides may be prepared by substituting an anhydride of the formula where r 6 is c 1 - c 6 alkyl , for acetic anhydride in procedure 5 to yield compounds of the formula vi , wherein x is trifluoromethyl : to a solution of n -[ 4 -( 5 - aryl - 3 - trifluoromethylpyrazolin - 1 - yl ) phenylsulfonyl ] acetamide ( 5 mmol ) in ethanol ( 100 ml ), sodium hydroxide ( 5 mmol in 20 ml of water ) is added and stirred for 5 hours . the solution is then concentrated in vacuum to give a solid hydrated sodium salt of 1 -( 4 - sulfamylphenyl )- 3 - trifluoromethyl - 5 - aryl - 2 - pyrazoline . salts of other sulfonamides may be prepared in the same manner by substituting the appropriate amide according to formula v as the starting compound . n -[ 4 -( 5 - aryl - 3 -[ alkyl or optionally substituted aryl ] pyrazolin - 1 - yl ) phenylsulfonyl ] acetamides according to formula v ( x = c 1 - c 6 alkyl or optionally substituted or di - substituted phenyl ) are prepared according to procedure 5 , substituting the appropriate 1 -( 4 - sulfamylphenyl )- 3 -( alkyl or optionally substituted phenyl )- 5 - aryl - 2 - pyrazoline for 1 -( 4 - sulfamylphenyl )- 3 - trifluoromethyl - 5 - aryl - 2 - pyrazoline as the staring material . in similar fashion , sulfonamides according to formula v ( x = c 1 - c 6 alkyl or optionally substituted or di - substituted phenyl ), other than acetamides , may be prepared by substituting the appropriate anhydride for acetic anhydride in procedure 5 . these compounds may be converted to salts according to procedure 6 . the compounds of the invention preferably are characterized by a selectivity ratio for cox - 2 inhibition over cox - 1 inhibition of at least about 50 , more preferably at least about 100 . cox inhibition may be determined in vitro by enzyme assays well - known to those skilled in the art , such as the enzyme assay method described later herein . the compounds of the present invention may take the form or pharmaceutically acceptable salts . the term “ pharmaceutically acceptable salts ”, embraces salts commonly used to form alkali metal salts and to form addition salts of free acids or free bases . where reference is made to “ compound of formula i ( or formula v )” or a “ compound of the invention ”, it is understood that pharmaceutically acceptable salts are also included . the nature of the salt is not critical , provided that it is pharmaceutically - acceptable . suitable pharmaceutically acceptable acid addition salts may be prepared from an inorganic acid or from an organic acid . examples of such inorganic acids are hydrochloric , hydrobromic , hydroiodic , nitric , carbonic , sulfuric and phosphoric acid . appropriate organic acids may be selected from aliphatic , cycloaliphatic , aromatic , araliphatic , heterocyclic , carboxylic and sulfonic classes of organic acids , example of which are formic , acetic , propionic , succinic , glycolic , gluconic , lactic , malic , tartaric , citric , ascorbic , glucuronic , maleic , fumaric , pyruvic , aspartic , glutamic , benzoic , anthranilic , mesylic , salicyclic , salicyclic , 4 - hydroxybenzoic , phenylacetic , mandelic , embonic ( pamoic ), methanesulfonic , ethanesulfonic , benzenesulfonic , pantothenic , 2 - hydroxyethanesulfonic , toluenesulfonic , sulfanilic , cyclohexylaminosulfonic , stearic , algenic , beta - hydroxybutyric , salicyclic , galactaric and galacturonic acid . suitable pharmaceutically acceptable base addition salts of compounds of formula include metallic salts made from calcium , lithium , magnesium , potassium , sodium and zinc or organic salts made from n , n ′- dibenzylethylenediamine , chloroprocaine , choline , diethanolamine , ethylenediamine , meglumine ( n - methylglucamine ) and procaine . all of these salts may be prepared by conventional means from the corresponding compound of formula i or v by reacting , for example , the appropriate acid or base with the compound of formula i or v . the compounds of the present invention may be administered in the form of a pharmaceutical composition , in combination with a pharmaceutically acceptable carrier . the active ingredient in such formulations may comprise from 0 . 1 to 99 . 99 weight percent . by “ pharmaceutically acceptable carrier ” is meant any carrier , diluent or excipient which is compatible with the other ingredients of the formulation and to deleterious to the recipient . the compounds of the invention may be administered to individuals ( animals , most particularly mammals including humans ) afflicted with any disorder characterized by undesirable prostaglandin production resulting from cyclooxygenase activity , particularly cox - 2 activity (“ cyclooxygenase - mediated disorder ”). in particular , the compounds of the invention are believed useful in treating inflamation and inflamation - related disorders , by administering to a subject having or susceptible to such inflamation or inflamation - related disorder and effective amount of a compound according to formula i . inflamation is associated with a variety of disease conditions . for a list of such disease conditions treatable by cyclooxygenase inhibitors , and cox - 2 inhibitors in particular , see u . s . pat . nos . 5 , 604 , 253 and 5 , 908 , 852 , the entire disclosures of which are incorporated herein by reference . such conditions include , for example , arthritis , including but not limited to rheumatoid arthritis , spondyloarthropathies , gouty arthritis , osteoarthritis , systemic lupus erythematosus and juvenile arthritis . such conditions further include rheumatic fever , symptoms associated with influenza or other viral infections , common cold , low back and neck pain , dysmenorrhea , headache , toothache , sprains and strains , myositis , neuralgia , synovitis , gout and ankylosing spondylitis , bursitis , and following surgical and dental procedures . the compounds of the invention are believed useful as analgesics for treating or alleviating all forms of pain . the compounds are believed useful in the treatment of other disorders including asthma , bronchitis , tendinitis , bursitis ; skin related conditions such as psoriasis , eczema , burns and dermatitis ; gastrointestinal conditions such as inflammatory bowel disease , crohn &# 39 ; s disease , gastritis , irritable bowel syndrome and ulcerative colitis and for the prevention of colorectal cancer ; the treatment of inflamation in such diseases as vascular diseases , migraine headaches , periarteritis nodosa , thyroiditis , aplastic anemia , hodgkin &# 39 ; s disease , sclerodoma , type i diabetes , myasthenia gravis , sarcoidosis , nephrotic syndrome , behcet &# 39 ; s syndrome , polymyositis , gingivitis , hypersensitivity , conjunctivitis , swelling occurring after injury , myocardial ischemia , and the like . the compounds of the invention are believed useful as antipyretics for the treatment of fever . in addition , compounds of the invention may inhibit cellular neoplastic transformations and metastatic tumor growth and hence can be used in the treatment of cancer . in particular , the present invention provides a method for treating or preventing a neoplasia that produces a prostaglandin in a subject in need of such treatment or prevention , the method comprises treating the subject with a therapeutically effective amount of a compound of formula i or v . the term “ neoplasia ” includes neoplasia that produce prostaglandins or express a cyclooxygenase , including both benign and cancerous tumors , growths and polyps . neoplasias believed treatable with cyclooxygenase inhibitors are discussed in u . s . pat . no . 5 , 972 , 986 , the entire disclosure of which is incorporated herein by reference . the compounds may be used to inhibit the growth or an established neoplasm , i . e ., to induce regression , or to prevent or delay the onset of the neoplasm . according to u . s . pat . no . 5 , 972 , 986 , neoplasias that produce prostaglandins , and which are therefore believed treatable with the compounds of the invention , include brain cancer , bone cancer , epithelial cell - derived neoplasia ( epithelial carcinoma ) such as basal cell carcinoma , adenocarcinoma , gastrointestinal cancer such as lip cancer , mouth cancer , esophageal cancer , small bowel cancer and stomach cancer , colon cancer , liver cancer , bladder cancer , pancreas cancer , ovary cancer , cervical cancer , lung cancer , breast cancer and skin cancer , such as squamous cell and basal cell cancers , prostate cancer , renal cell carcinoma , and other known cancers that effect epithelial cells throughout the body . the compounds of the invention may also be useful in the treatment of angiogenesis - mediated disorders . thus , a method fortreating , inhibiting or delaying the onset of an angiogenesis - mediated disorder in a subject is provided comprising administering to a subject in need of such treatment an effective amount of a compound according to the present invention . angiogenesis - mediated disorders which may be treatable with cyclooxygenase inhibitors are discussed in u . s . pat . no . 6 , 025 , 353 , the entire disclosure of which is incorporated herein by reference . according to u . s . pat . no . 6 , 025 , 353 , such disorders include , for example , metastasis , corneal graft rejection , ocular neovascularization , retinal neovascularization , diabetic retinopathy , retrolental fibroplasia , neovascular glaucoma , gastric ulcer , infantile hemaginomas , angiofibroma of the nasopharynx , avascular necrosis of bone , and endometriosis . the compounds may be administered by any route , including oral and parenteral administration . parenteral administration includes , for example , intravenous , intramuscular , intraarterial , intraperitoneal , intranasal , rectal , or subcutaneous administration . the active agent is preferably administered with a pharmaceutically acceptable carrier selected on the basis of the selected route of administration and standard pharmaceutical practice . the active agent may be formulated into dosage forms according to standard practices in the field of pharmaceutical preparations . see alphonso gennaro , ed ., remington &# 39 ; s pharmaceutical sciences , 18th ed ., ( 1990 ) mack publishing co ., easton , pa . suitable dosage forms may comprise , for example , tablets , capsules , solutions , parenteral solutions , troches , suppositories , or suspensions . for parenteral administration , the active agent may be mixed with a suitable carrier or diluent such as water , an oil , saline solution , aqueous dextrose ( glucose ) and related sugar solutions , or a glycol such as propylene glycol or polyethylene glycol . solutions for parenteral administration preferably contain a water soluble salt of the active agent . stabilizing agents , antioxidizing agents and preservatives may also be added . suitable antioxidizing agents include sulfite , ascorbic acid , citric acid and its salts , and sodium edta . suitable preservatives include benzalkonium chloride , methyl - or propyl - paraben , and chlorbutanol . for oral administration , the active agent may be combined with one or more solid inactive ingredients for the preparation of tablets , capsules , or other suitable oral dosage forms . for example , the active agent may be combined with carboxymethylcellulose calcium , magnesium stearate , mannitol and starch , and then formed into tablets by conventional tableting methods . the specific dose of compound according to the invention to obtain therapeutic benefit will , of course , be determined by the particular circumstances of the individual patient including , the size , weight , age and sex of the patient , the nature and stage of the disease , the aggressiveness of the disease , and the route of administration . for example , a daily dosage of from about 0 . 01 to about 150 mg / kg / day may be utilized . higher or lower doses are also contemplated . the compounds of the present invention are optically active due to the presence of a chiral carbon atom at position 5 of the pyrazoline nucleus : other chiral carbon atoms may also be present . the present invention is meantto comprehend diastereomers aswell as their racemic and resolved , enantiomerically pure forms and pharmaceutically acceptable salts thereof . isolated optical isomers may be purified from racemic mixtures by well - known chiral separation techniques . according to one such method , a racemic mixture of a compound having the structure of formula i or v , or chiral intermediate thereof , is separated into 99 % wt . % pure optical isomers by hplc using a suitable chiral column , such as daicel chiralpak ad ( daicel chemical industries , ltd ., tokyo , japan ). this column contains a packing of amylose tris ( 3 , 5 - dimethylphenyl ) carbamate coated on a 10 μm silica - gel substrate . the column has a size of 250 × 4 . 6 mm ( l × i . d .). the column is operated according to the manufacturer &# 39 ; s instructions . a flow rate should be maintained that will result in column pressures of less than 430 psi ( 30 kg / cm2 ). a typical flow rate is 1 . 0 ml / min . the operating temperature range is 0 ° c .- 40 ° c . the maximum operating pressure is 1200 psi . one suitable mobile phase system is hexane / 2 - propanol ( 100 / 0 to 0 / 100 v / v ). a typical hexane / 2 - propanol mobile phase is hexane / 2 - propanol ( 90 / 10 v / v ). another suitable mobile phase system is hexane / ethanol ( 100 / 0 to 85 / 15 v / v ), ( 40 / 60 to 0 / 100 v / v ). suitable mobile phase modifiers include n , n - diethylamine for a basic sample , and trifluoroacetic acid for an acidic sample . the practice of the invention is illustrated by the following non - limiting examples . a . trans - 1 , 1 , 1 - trifluoro - 4 - phenyl - 3 - buten - 2 - one was prepared according to procedure 1 from 1 , 1 , 1 - trifluoroacetone and benzylaldehyde . b . a solution of trans - 1 , 1 , 1 - trifluoro - 4 - phenyl - 3 - buten - 2 - one ( 5 mmol ) and 4 - sulfamylphenyl hydrazine hydrochloride ( 6 mmol ) was subjected to procedure 3 . the title compound was obtained in 73 % yield , m . p . 132 - 135 ° c . ; c , h analysis ( c 18 h 15 so 2 n 4 f 3 . h 2 o ): table 1 , examples 2 - 23 , lists additional compounds which are by reacting a trans - 1 , 1 , 1 - trifluoro - 4 -( substituted ) phenyl - 3 - buten - 2 - one ( 5 mmol ) and 4 - sulfamylphenyl hydrazine hydrochloride according to procedure 3 . b . a solution of trans - 1 , 1 , 1 - trifluoro - 4 -( 3 - indolyl )- 3 - buten - 2 - one ( 5 mmol ) and 4 - sulfamylphenyl hydrazine hydrochloride ( 6 mmol ) was subjected to procedure 3 . the title compound was obtained in 82 % yield , m . p . 178 - 180 ° c . ; c , h analysis ( c 16 h 14 so 2 n 4 f 3 ): table 2 , examples 25 - 30 , lists additional compounds which are prepared by reacting trans - 1 , 1 , 1 - trifluoro - 4 - aryl - 3 - buten - 2 - one and 4 - sulfamylphenyl hydrazine hydrochloride according to procedure 3 . cyclooxygenase activity of ovine cox - 1 ( oxford biomedical research inc .) and human recombinant cox - 2 ( oxford biomedical research inc .) was assayed by a thin layer chromatography ( tlc ) method as follows . all inhibitors were dissolved in dimethyl sulfoxide to a stock solution of 5mm . human recombinant cox - 2 ( 3 units ) or ovine cox - 1 ( 15 units ) was incubated with inhibitors at several concentrations in a solution containing 100 mm tris - hcl , ph7 . 8 , 500 μm phenol and hematin for 90 to 120 minutes at room temperature ( 24 ° c .). in controls , equal volumes of dmso without drug were added to the incubation mixture . after incubation for 90 - 120 minutes , [ 1 - 14 c ] arachidonic acid ( 50 μm , 51 mci / mmol ) ( dupont nen ) was added and incubated at 37 ° c . for 2 minutes . the reaction was terminated by extraction with 1 ml of ethyl acetate . the ethyl acetate layer was transferred into a fresh tube and evaporated to dryness in a speedvac vacuum dryer . the contents of the tubes were reconstituted in 20 ml of ethyl acetate and spotted on a tlc plate ( j . t . baker , phillipsburg , n . j .) and developed in a mobile phase containing chloroform / methanol ( 95 : 5 ) at4 ° c . radiolabeled prostanoid compounds ( the products of cox enzymatic reaction with radiolabeled arachidonic acid substrate ) were quantitated with a radioactivity scanner ( fuji , phosphorimager ). the percentage of total products observed at different inhibitor concentrations was divided by the percentage of the products observed for protein samples pre incubated for the same time with dmso . the results are shown in table 4 . the example 1 and 2 compounds are more than one thousand times more active in inhibiting cox - 2 compared to cox - 1 . the example 1 and 24 compounds were compared to the cox - 2 inhibitor celecoxib in inhibiting the growth of dld - 1 cells in soft agar . dld - 1 cells are human colorectal carcinoma cells that overexpress cox - 2 . dld - 1 cells grow in soft agar and form tumors in nude mice . the soft agar assay was performed as follows . a layer of bottom agar ( 8 % noble agar ) was placed onto 60 mm 2 tissue culture dishes . the tumor cells were trypsinized from normal growth flasks while in exponential growth . the cells were counted by using a hemacytometer and 1 . 0 × 10 5 cells were placed into the top agar mixture containing growth medium , 4 % noble agar and various concentrations of drugs . the concentration range was normally between 10 μm to 75 μm . the cells were not refed during the assay system ; therefore , the cells were treated with one dose of the agents . the plates were stained 20 days later with a 0 . 05 % ( w / v ) nitroblue tetrazolium solution ( which stains only viable cells ) for 48 hours . the results are shown in fig1 the y - axis being the percent of cell colonies remaining in comparison to untreated control cells . even at the highest concentration tested , celecoxib obtained only about partial inhibition , compared to 100 % for the compounds of the invention . the present invention may be embodied in other specific forms without departing from the spirit or essential attributes thereof and , accordingly , reference should be made to the appended claims , ratherthan to the foregoing specification , as indication the scope of the invention .